Please Wait.....
Report
U.S. Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-04-01 I 456 Pages I Data Bridge Market Research
The U.S. pancreatic cancer diagnostics market is projected to register a healthy CAGR of 8.3% in the forecast period of 2022 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2022 to 2030.
Market Segmentation
U.S. Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Region (Southern U.S., Western U.S., Mid-Western U.S., and North-Eastern U.S.) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the U.S. pancreatic cancer diagnostics market are:
- Novel technological advancements in pancreatic diagnostics
- Growing awareness of pancreatic cancer and increasing healthcare expenditure
Market Players
Some of the major market players operating in the U.S. pancreatic cancer diagnostics market are:
- Agilent Technologies, Inc.
- BD
- Biological Dynamics
- CANON MEDICAL SYSTEMS CORPORATION
- ClearNote Health
- CTK Biotech, Inc.
- Danaher.
- Exact Sciences Corporation
- F. Hoffman- La Roche Ltd
- FUJIFILM Holdings America Corporation
- GRAIL
- Immunovia
- Koninklijke Philips N.V.
- Laboratory Corporation of America Holdings
- MP BIOMEDICALS
- Myriad Genetics, Inc.
- QIAGEN
- Quest Diagnostics Incorporated
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW 54
1.4 CURRENCY AND PRICING 57
1.5 LIMITATIONS 57
1.6 MARKETS COVERED 57
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 DBMR TRIPOD DATA VALIDATION MODEL 62
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.6 MULTIVARIATE MODELLING 66
2.7 MARKET APPLICATION COVERAGE GRID 67
2.8 PRODUCT LIFELINE CURVE 68
2.9 DBMR MARKET POSITION GRID 69
2.10 SECONDARY SOURCES 70
2.11 ASSUMPTIONS 70
3 EXECUTIVE SUMMARY 71
4 U.S. CHRONIC PANCREATITIS TESTING MARKET 74
4.1 CHRONIC PANCREATITIS 74
4.2 LABORATORY TESTING 74
4.3 CHRONIC PANCREATITIS DIAGNOSE 74
4.4 PANCREATIC FUNCTION TESTS 76
4.4.1 INDIRECT PANCREATIC FUNCTION TESTS 76
4.4.2 DIRECT PANCREATIC FUNCTION TESTS 76
5 PREMIUM INSIGHTS 78
5.1 PESTEL MODEL 79
5.2 PORTER'S FIVE FORCES 80
5.3 EPIDEMIOLOGY 81
6 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 82
7 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 83
8 MARKET OVERVIEW 84
8.1 DRIVERS 86
8.1.1 GROWTH IN THE PREVALENCE OF PANCREATIC CANCER 86
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 86
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 87
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 87
8.2 RESTRAINTS 88
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 88
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 88
8.3 OPPORTUNITIES 89
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 89
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 90
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 90
8.4 CHALLENGES 91
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 91
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 91
9 IMPACT OF COVID-19 92
9.1 OVERVIEW 92
9.2 DEMAND SURGE FOR MEDICAL DIAGNOSTIC 92
9.3 GROWTH IN GOVERNMENT SPENDING ON HEALTHCARE 92
9.4 STRATEGIC INITIATIVES BY KEY PLAYERS 93
9.5 INCREASE IN THE PRICE OF TESTS KITS AND REAGENTS 93
10 OUTLOOK AND TREND OF THE MARKET AFTER COVID -19 94
11 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 95
11.1 OVERVIEW 96
11.2 IMAGING TEST 99
11.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 100
11.2.2 MAGNETIC RESONANCE IMAGING (MRI) 100
11.2.3 MR CHOLANGIOPANCREATOGRAPHY 101
11.2.4 MR ANGIOGRAPHY (MRA) 101
11.3 ULTRASOUND 101
11.3.1 ABDOMINAL ULTRASOUND 101
11.3.2 ENDOSCOPIC ULTRASOUND (EUS) 101
11.4 CHOLANGIOPANCREATOGRAPHY 101
11.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 102
11.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 102
11.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 102
11.5 POSITRON EMISSION TOMOHRAPHY (PET) 102
11.6 OTHERS 102
11.7 BIOPSY 102
11.8 CT-GUIDED NEEDLE BIOPSY 103
11.9 FINE NEEDLE ASPIRATION (FNA) 103
11.10 CORE NEEDLE BIOPSY 104
11.11 OTHERS 104
11.12 BLOOD TEST 104
11.13 LIVER FUNCTION TEST 105
11.14 TUMOR MARKER 105
11.14.1 CA 19-9 BIOMARKER TEST 105
11.14.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 105
11.14.3 CA 50 MARKER TEST 105
11.14.4 OTHERS 105
11.15 OTHERS 106
11.16 GENOMIC TEST 106
11.17 OTHERS 106
12 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 107
12.1 OVERVIEW 108
12.2 STAGE IV 111
12.3 STAGE III 111
12.4 STAGE II 112
12.4.1 STAGE IIA 112
12.4.2 STAGE IIB 112
12.5 STAGE I 113
12.5.1 STAGE IB 113
12.5.2 STAGE IA 113
12.6 STAGE 0 114
13 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 115
13.1 OVERVIEW 116
13.2 EXOCRINE TUMORS 119
13.2.1 INSTRUMENT-BASED PRODUCTS 120
13.2.2 PLATFORM-BASED PRODUCTS 120
13.2.3 KITS AND REAGENTS 120
13.2.4 OTHER CONSUMABLES 120
13.3 NEUROENDOCRINE TUMORS 120
13.3.1 INSTRUMENT-BASED PRODUCTS 121
13.3.2 PLATFORM-BASED PRODUCTS 121
13.3.3 KITS AND REAGENTS 121
13.3.4 OTHER CONSUMABLES 121
14 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 122
14.1 OVERVIEW 123
14.2 INSTRUMENT-BASED PRODUCTS 126
14.2.1 IMAGING 127
14.2.2 BIOPSY 127
14.3 PLATFORM-BASED PRODUCTS 127
14.3.1 NEXT-GENERATION SEQUENCING 128
14.3.2 MICROARRAYS 128
14.3.3 PCR 128
14.3.4 OTHERS 128
14.4 KITS AND REAGENTS 128
14.4.1 CA19-9 PANCREATIC CANCER TEST KITS 129
14.4.1.1 ELISA TEST KITS 130
14.4.1.2 CASETTE TEST KITS 130
14.4.1.3 OTHERS 130
14.4.2 CEA PANCREATIC CANCER TEST KITS 130
14.4.2.1 ELISA TEST KITS 130
14.4.2.2 CASETTE TEST KITS 130
14.4.2.3 OTHERS 130
14.5 OTHERS 131
15 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 132
15.1 OVERVIEW 133
15.2 FLUORESCENT IN SITU HYBRIDIZATION 136
15.3 NEXT GENERATION SEQUENCING 136
15.4 FLUORIMMUNOASSAY 137
15.5 COMPARATIVE GENOMIC HYBRIDIZATION 137
15.6 IMMUNOHISTOCHEMICAL 138
15.7 OTHERS 138
16 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 139
16.1 OVERVIEW 140
16.2 SCREENING 143
16.2.1 INSTRUMENT-BASED PRODUCTS 143
16.2.2 PLATFORM-BASED PRODUCTS 143
16.2.3 KITS AND REAGENTS 143
16.2.4 OTHER CONSUMABLES 144
16.3 DIAGNOSTIC AND PREDICTIVE 144
16.3.1 INSTRUMENT-BASED PRODUCTS 145
16.3.2 PLATFORM-BASED PRODUCTS 145
16.3.3 KITS AND REAGENTS 145
16.3.4 OTHER CONSUMABLES 145
16.4 PROGNOSTIC 145
16.4.1 INSTRUMENT-BASED PRODUCTS 146
16.4.2 PLATFORM-BASED PRODUCTS 146
16.4.3 KITS AND REAGENTS 146
16.4.4 OTHER CONSUMABLES 146
16.5 RESEARCH 146
16.5.1 INSTRUMENT-BASED PRODUCTS 147
16.5.2 PLATFORM-BASED PRODUCTS 147
16.5.3 KITS AND REAGENTS 147
16.5.4 OTHER CONSUMABLES 147
17 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 148
17.1 OVERVIEW 149
17.2 HOSPITALS 152
17.3 DIAGNOSTIC CENTERS 152
17.4 CANCER RESEARCH CENTERS 153
17.5 ACADEMIC INSTITUTES 153
17.6 AMBULATORY SURGICAL CENTERS 153
17.7 OTHERS 154
18 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 155
18.1 OVERVIEW 156
18.2 DIRECT TENDER 159
18.3 RETAIL SALES 159
18.4 OTHERS 159
19 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 160
19.1 OVERVIEW 161
19.2 U.S. 161
19.3 SOUTHERN U.S. 163
19.3.1 FLORIDA 171
19.3.2 TEXAS 178
19.3.3 NORTH CAROLINA 185
19.3.4 GEORGIA 193
19.3.5 VIRGINIA 201
19.3.6 TENNESSEE 209
19.3.7 REST OF SOUTHERN U.S. 216
19.4 WESTERN U.S. 217
19.4.1 ILLINOIS 228
19.4.2 OHIO 239
19.4.3 MICHIGAN 250
19.4.4 INDIANA 261
19.4.5 MISSOURI 272
19.4.6 MINNESOTA 283
19.4.7 REST OF WESTERN U.S. 294
19.5 MID-WESTERN U.S. 295
19.5.1 CALIFORNIA 303
19.5.2 WASHINGTON 311
19.5.3 ARIZONA 319
19.5.4 COLORADO 327
19.5.5 OREGON 335
19.5.6 NEVADA 343
19.5.7 REST OF MID-WESTERN U.S. 351
19.6 NORTH-EASTERN U.S. 352
19.6.1 NEW YORK 360
19.6.2 PENNSYLVANIA 368
19.6.3 NEW JERSEY 376
19.6.4 MASSACHUSETTS 384
19.6.5 MARYLAND 392
19.6.6 CONNECTICUT 400
19.6.7 REST OF NORTH-EASTERN U.S. 408
20 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 409
20.1 COMPANY SHARE ANALYSIS: EUROPE 409
21 SWOT ANALYSIS 410
22 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 411
22.1 F. HOFFMANN- LA ROCHE LTD 411
22.1.1 COMPANY SNAPSHOT 411
22.1.2 SWOT 412
22.1.3 REVENUE ANALYSIS 412
22.1.4 PRODUCT PORTFOLIO 413
22.1.5 RECENT DEVELOPMENT 413
22.2 KONINKLIJKE PHILIPS N.V. 414
22.2.1 COMPANY SNAPSHOT 414
22.2.2 REVENUE ANALYSIS 414
22.2.3 PRODUCT PORTFOLIO 415
22.2.4 RECENT DEVELOPMENTS 415
22.3 CANON MEDICAL SYSTEMS CORPORATION 416
22.3.1 COMPANY SNAPSHOT 416
22.3.2 REVENUE ANALYSIS 416
22.3.3 PRODUCT PORTFOLIO 417
22.3.4 RECENT DEVELOPMENT 417
22.4 GRAIL 418
22.4.1 COMPANY PROFILE 418
22.4.2 PRODUCT PORTFOLIO 418
22.4.3 RECENT DEVELOPMENT 418
22.5 SIEMENS HEALTHCARE GMBH 419
22.5.1 COMPANY SNAPSHOT 419
22.5.2 REVENUE ANALYSIS 419
22.5.3 PRODUCT PORTFOLIO 420
22.5.4 RECENT DEVELOPMENT 420
22.6 AGILENT TECHNOLOGIES, INC. 421
22.6.1 COMPANY PROFILE 421
22.6.2 REVENUE ANALYSIS 421
22.6.3 PRODUCT PORTFOLIO 422
22.6.4 RECENT DEVELOPMENT 422
22.7 BIOLOGICAL DYNAMICS 423
22.7.1 COMPANY SNAPSHOT 423
22.7.2 SWOT 423
22.7.3 PRODUCT PORTFOLIO 424
22.7.4 RECENT DEVELOPMENTS 424
22.8 BD 425
22.8.1 COMPANY SNAPSHOT 425
22.8.2 REVENUE ANALYSIS 425
22.8.3 PRODUCT PORTFOLIO 426
22.8.4 RECENT DEVELOPMENT 426
22.9 CLEARNOTE HEALTH 427
22.9.1 COMPANY SNAPSHOT 427
22.9.2 SWOT 427
22.9.3 PRODUCT PORTFOLIO 428
22.9.4 RECENT DEVELOPMENT 428
22.10 CTK BIOTECH, INC. 429
22.10.1 COMPANY PROFILE 429
22.10.2 PRODUCT PORTFOLIO 429
22.10.3 RECENT DEVELOPMENT 429
22.11 DANAHER. 430
22.11.1 COMPANY SNAPSHOT 430
22.11.2 SWOT 431
22.11.3 REVENUE ANALYSIS 431
22.11.4 PRODUCT PORTFOLIO 432
22.11.5 RECENT DEVELOPMENTS 432
22.12 EXACT SCIENCES CORPORATION 433
22.12.1 COMPANY SNAPSHOT 433
22.12.2 SWOT 434
22.12.3 REVENUE ANALYSIS 434
22.12.4 PRODUCT PORTFOLIO 435
22.12.5 RECENT DEVELOPMENT 435
22.13 FUJIFILM HOLDINGS AMERICA CORPORATION 436
22.13.1 COMPANY SNAPSHOT 436
22.13.2 REVENUE ANALYSIS 436
22.13.3 PRODUCT PORTFOLIO 437
22.13.4 RECENT DEVELOPMENT 437
22.14 IMMUNOVIA 438
22.14.1 COMPANY SNAPSHOT 438
22.14.2 SWOT 438
22.14.3 REVENUE ANALYSIS 439
22.14.4 PRODUCT PORTFOLIO 439
22.14.5 RECENT DEVELOPMENT 439
22.15 LABORATORY CORPORATION OF AMERICA HOLDINGS 440
22.15.1 COMPANY SNAPSHOT 440
22.15.2 REVENUE ANALYSIS 440
22.15.3 PRODUCT PORTFOLIO 441
22.15.4 RECENT DEVELOPMENTS 441
22.16 MP BIOMEDICALS. 442
22.16.1 COMPANY PROFILE 442
22.16.2 PRODUCT PORTFOLIO 442
22.16.3 RECENT DEVELOPMENT 442
22.17 MYRIAD GENETICS, INC. 443
22.17.1 COMPANY SNAPSHOT 443
22.17.2 REVENUE ANALYSIS 443
22.17.3 PRODUCT PORTFOLIO 444
22.17.4 RECENT DEVELOPMENT 444
22.18 QIAGEN 445
22.18.1 COMPANY SNAPSHOT 445
22.18.2 REVENUE ANALYSIS 445
22.18.3 PRODUCT PORTFOLIO 446
22.18.4 RECENT DEVELOPMENT 446
22.19 QUEST DIAGNOSTICS INCORPORATED 447
22.19.1 COMPANY SNAPSHOT 447
22.19.2 SWOT 448
22.19.3 REVENUE ANALYSIS 448
22.19.4 PRODUCT PORTFOLIO 449
22.19.5 RECENT DEVELOPMENT 449
22.20 THERMO FISHER SCIENTIFIC INC. 450
22.20.1 COMPANY SNAPSHOT 450
22.20.2 REVENUE ANALYSIS 450
22.20.3 PRODUCT PORTFOLIO 451
22.20.4 RECENT DEVELOPMENT 451
23 QUESTIONNAIRE 452
24 RELATED REPORTS 456
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security